Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Looking For Senior Leader In New Drugs Office To Oversee Substance Use Disorder Issues

Oct 27 2023

• By Derrick Gingery

Related Content

Green Light For First OTC Naloxone In US After FDA Raises Caution Flag During Advisory Panel

Mar 30 2023

Opioid Prescriber Education Program May Become Mandatory; FDA Cites Failures In Voluntary System

Sep 09 2021

New Opioid Labeling Further Constrains Use, Urges Prescribing Only By Docs ‘Knowledgeable’ About Risks

Apr 18 2023

Opioids, Abortion, And Drug Advertising: How A Califf-Led FDA Might Address Hot Button Rx Topics

Dec 15 2021

US FDA's Words Matter: Sharpless Says Injectable Naloxone OK For Community Distribution

Sep 26 2019

Opioid Blister Packs Need Study Before Mandate, Groups Urge

Aug 12 2019

US FDA Elevates Controlled Substances Coordinator To New Deputy CDER Director Role

Jul 18 2022

‘Opioids’ Is Missing From The US FDA’s Overdose Prevention Framework Title On Purpose

Sep 14 2022

Califf Says Opioid Labeling Changes, Withdrawals Still Possible

Apr 13 2022

Additional Topics

United States FDA Leadership Regulation Drug Review Neurology BioPharmaceutical

More from US FDA

More from Agency Leadership

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window